StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/302% above fair value
$64.63−1.20 (-1.82%)

Close on Nov 20, 2026Market cap $15.77BP/E 19.4Yield –

Exelixis free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Exelixis's free cash flow for the twelve months ending Oct 2, 2026 was $1.16B, up 48.9% year over year. For fiscal 2025 it was $875.84M, up 30.4% from the year before. The highest annual figure on record is $875.84M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Jan 2, 2026$875.84M+30.4%
FY2024Jan 3, 2025$671.54M+129.3%
FY2023Dec 29, 2023$292.86M-12.6%
FY2022Dec 30, 2022$334.91M-3.4%
FY2021Dec 31, 2021$346.58M+94.0%
FY2020Jan 1, 2021$178.64M-65.3%
FY2019Jan 3, 2020$514.12M+34.4%
FY2018Dec 28, 2018$382.42M+164.7%
FY2017Dec 29, 2017$144.47M-30.8%
FY2016Dec 31, 2016$208.70M–
FY2015Dec 31, 2015-$141.50M–
FY2014Dec 31, 2014-$235.88M–
FY2013Dec 31, 2013-$200.94M–
FY2012Dec 31, 2012-$125.86M–
FY2011Dec 31, 2011-$160.22M–
FY2010Dec 31, 2010-$102.86M–
FY2009Dec 31, 2009-$20.50M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Oct 2, 2026$277.47M-3.9%
Q2 FY2026Jul 3, 2026$300.93M+552.0%
Q1 FY2026Apr 3, 2026$250.34M+20.1%
Q4 FY2025Jan 2, 2026$332.36M+40.7%
Q3 FY2025Oct 3, 2025$288.84M+9.8%
Q2 FY2025Jul 4, 2025$46.16M-59.1%
Q1 FY2025Apr 4, 2025$208.49M+252.6%
Q4 FY2024Jan 3, 2025$236.29M–
Q3 FY2024Sep 27, 2024$263.14M+143.7%
Q2 FY2024Jun 28, 2024$112.98M-1.8%
Q1 FY2024Mar 29, 2024$59.13M-18.3%
Q4 FY2023Dec 29, 2023-$2.56M-104.0%
Q3 FY2023Sep 29, 2023$107.99M+2.8%
Q2 FY2023Jun 30, 2023$115.04M+383.5%
Q1 FY2023Mar 31, 2023$72.38M-49.1%
Q4 FY2022Dec 30, 2022$63.98M-29.3%
Q3 FY2022Sep 30, 2022$105.03M+52.6%
Q2 FY2022Jul 1, 2022$23.79M-85.2%
Q1 FY2022Apr 1, 2022$142.11M+446.9%
Q4 FY2021Dec 31, 2021$90.49M+376.2%
Q3 FY2021Oct 1, 2021$68.81M+482.7%
Q2 FY2021Jul 2, 2021$161.29M+70.3%
Q1 FY2021Apr 2, 2021$25.99M-51.1%
Q4 FY2020Jan 1, 2021$19.00M-87.4%
Q3 FY2020Oct 2, 2020$11.81M-83.9%
Q2 FY2020Jul 3, 2020$94.71M-27.4%
Q1 FY2020Apr 3, 2020$53.11M-66.7%
Q4 FY2019Jan 3, 2020$150.76M+48.2%
Q3 FY2019Sep 27, 2019$73.56M-50.8%
Q2 FY2019Jun 28, 2019$130.52M+109.7%
Q1 FY2019Mar 29, 2019$159.29M+131.3%
Q4 FY2018Dec 28, 2018$101.70M+185.2%
Q3 FY2018Sep 28, 2018$149.64M+307.6%
Q2 FY2018Jun 29, 2018$62.23M+1440.0%
Q1 FY2018Mar 30, 2018$68.86M+1.2%
Q4 FY2017Dec 29, 2017$35.66M-57.8%
Q3 FY2017Sep 30, 2017$36.71M–
Q2 FY2017Jun 30, 2017$4.04M–
Q1 FY2017Mar 31, 2017$68.05M–
Q4 FY2016Dec 31, 2016$84.52M–

More Exelixis figures

See a number that looks wrong?